At present, Roche Group has two main research directions and businesses, one is pharmaceutical, and the second is diagnostics.

Roche's pharmaceutical technology has always been very famous, for example, during the domestic flu epidemic, there was a very popular drug called oseltamivir, which is an antiviral drug, and he came from Roche Group.

Danio, the current director of the pharmaceutical department, it was he who invited Bona and others to compete with Bai Ye Research Institute in the field of oncology.

The senior management of the Roche Group agreed with Danio's behavior this time, and even unanimously approved.

Why?

Because, in the past few days, after the news of Roche Group, Bona, Considine, and Mostein came out, they instantly occupied the hot spot of public opinion, and also brought about a rise in stock prices.

Nothing beats the benefits that come with benefits.

Seeing such a good response, the current CEO of Roche Group was very cooperative with Danio's behavior and strongly supported various policies and finances.

Even seven or eight Nobel laureates, including Bona and others, have been invited, and they are bound to make great achievements in this field and do something big.

Danio looked at Boehner and said with a smile, "Professor Bona, do you think it would be more appropriate for us to start with that field first?"

PropNex put down the information in his hand, which said that this time Roche Group has invested in this research and has many strong strengths: "The field of tumor is very large, although it is only a discipline, but this discipline basically covers most of the fields of internal medicine, and there are cancers in each field, and the cell specificity of each system determines that each disease has different differences, which is a more complex and difficult work." But...... I'll be honest, I don't want to study something with Bai Ye, or rather, I don't think it's good for us to study something with Bai Ye at the same time. ”

"It is true that the stock price of the Roche Group is rising now, but I believe that if we and Bai Ye study something in the same field at the same time, no one can guarantee that whoever will be able to find out first, and the two tigers will definitely hurt each other, which is not a wise behavior. ”

"So, I think, we can start with another tumor, that is, to conduct research in different directions with Bai Ye, if he studies lung disease, we will do stomach cancer, if he wants to do glioma, we will do stromal tumor, all in all, don't crash!"

All of you here are human spirits, the kind that are outstanding, and when Boehner's words came out, everyone understood what he meant.

Everyone's eyes lit up, because Boehner's suggestion was very constructive.

After hearing Boena's words, Danio immediately felt that the money was not spent in vain, and his face was happy, just like Boehner said, no one is God, and no one can guarantee that their research will be better than the other.

In case of a collision with Bai Ye, and the forklift driven by Bai Ye is Santana driven by himself, this kind of collision can only be called a disaster!

For a listed group like Roche Group, it has a great impact.

After the company goes public, it is not a simple matter to care about reputation, credibility, and many things.

Danio asked, "Which direction do you think we should start with, and what field should we be engaged in?"

Bona seemed to have a solution and a way to solve this problem, but he was still silent for a while, and then said slowly: "Actually, I don't know much about Bai Ye's dynamics, and I really don't know what kind of research he will engage in next. ”

"However, I feel that Bai Ye is very likely to start with lung cancer!"

After speaking, Bona opened the notebook, then turned on the projection, and said to everyone: "During this time, I have made a detailed report on the market share of Roche Group and Pfizer Group in the field of oncology, you can take a look. ”

"This report is mainly within five years, Pfizer Group and Roche Group on the market share, praise rate, effective rate and other data of tumor research and development drugs, you can clearly see that in terms of market share, Pfizer's total market share is not much different from Roche, but take a closer look at the details and branches of each drug, we can find a lot of problems!"

"In the field of lung cancer, the advantages we Roche currently have are mainly concentrated in the drug CAIIS produced ten years ago, but in the past five years, the comparison results between us and Pfizer's lung cancer drugs show that they are 31.212% and 33.211%, Pfizer is two percentage points more than us, and these two percentage points do not seem to explain anything, but after I removed the old drug CAIIS, I found that we have fallen behind!"

"What does this mean, this shows that in the past five years, the drugs in the field of lung cancer have not achieved any particularly good market response, which is not a good thing for us, and all the lung cancer drugs currently used in China are basically all from us, because our old drugs entered relatively early in developing countries, we Shanghai Roche Group, Hong Kong Roche Group, China's Roche group and other pharmaceutical groups occupy most of the domestic market, but Pfizer is different, he occupies the market of developed countries, here is the proportion chart, you can take a look. ”

…………

Although Bona does not have a discerning eye, let alone the scientific and technological content of each drug, he is in the brain of a scientist, and he can get a lot of invisible information through a bunch of data.

After this information and data are continuously analyzed, it is possible to obtain a lot of useful essences, which are the things behind the phenomenon.

That's knowledge!

In fact, in the eyes of many people, a lot of impossibilities, but if you can analyze a lot of details and data, you can get a lot of seemingly magical and impossible data, this is the ability.

This is also the purpose of education and training.

The educational stage is mainly through learning how to acquire knowledge.

The graduate and doctoral stages are mainly about how you can use what you have learned to solve many practical problems.

And in this regard, major foreign universities have done very well, especially those famous schools with historical heritage, such as the Ivy League eight league schools and so on.

They pay special attention to the development of students in these areas, the application of what they have learned, and the emphasis on problem solving.

Therefore, this is also a relatively outstanding aspect of the education of high-level talents in foreign universities.

So, don't think that knowledge is useless, you just don't know how to use it yet.

In fact, knowledge is a plug-in!